GURUFOCUS.COM » STOCK LIST » Technology » Software » Hestia Insight Inc (OTCPK:HSTA) » Definitions » Current Deferred Revenue

Hestia Insight (Hestia Insight) Current Deferred Revenue : $0.00 Mil (As of Feb. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Hestia Insight Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Hestia Insight's current deferred revenue for the quarter that ended in Feb. 2024 was $0.00 Mil.

Hestia Insight Current Deferred Revenue Historical Data

The historical data trend for Hestia Insight's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hestia Insight Current Deferred Revenue Chart

Hestia Insight Annual Data
Trend Nov22 Nov23
Current Deferred Revenue
0.02 -

Hestia Insight Quarterly Data
Feb22 Aug22 Nov22 Feb23 Aug23 Nov23 Feb24
Current Deferred Revenue Get a 7-Day Free Trial 0.02 - - - -

Hestia Insight Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Hestia Insight's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hestia Insight (Hestia Insight) Business Description

Traded in Other Exchanges
N/A
Address
400 S. 4th Street, Suite 500, Las Vegas, NV, USA, 89101
Hestia Insight Inc provides strategic consulting and capital market advisory services for micro, small and medium-sized companies in the healthcare, biotech and fintech sectors. It also provides access to seed capital and mezzanine funding for qualified emerging companies in these industries. The firm derives all of its revenue from consulting services.